8-K: Cadrenal Therapeutics Upsizes ATM Stock Offering to $3.4M

Cadrenal Therapeutics, Inc. filed a prospectus supplement to offer and sell up to an additional $3.4 million of common stock through its existing at-the-market program.

Summary

• Filed a prospectus supplement on November 18, 2025, in connection with its at-the-market (ATM) offering program.
• The company can offer and sell up to an additional $3,438,062 of common stock from time to time.
• Sales will be conducted through H.C. Wainwright & Co., LLC as the sales agent.
• This offering is pursuant to an existing ATM Agreement dated March 11, 2024.
• Prior to this filing, the company had already sold an aggregate of $9,386,964 of common stock under the same ATM Agreement.
• The company retains discretion over the sales parameters, including the number of shares, time period, daily limits, and minimum price.
• H.C. Wainwright & Co., LLC will receive compensation of 3.0% of the gross sales price for shares sold through them.

Sentiment

Score: 5

Explanation: The filing announces a procedural step for a potential capital raise through an existing at-the-market offering. While it provides financial flexibility, it also introduces potential dilution for shareholders, balancing the sentiment to neutral.

Positives

• Provides the company with additional financial flexibility and access to capital to fund operations and strategic initiatives.
• Leverages an existing 'at-the-market' facility, allowing for efficient and opportunistic capital raising without a large, single-event offering.

Negatives

• Potential dilution for existing shareholders due to the issuance of new common stock.
• The 3.0% sales agent compensation reduces the net proceeds received by the company from the offering.

Risks

• The ATM Agreement can be terminated by either the company or Wainwright under certain circumstances, including a material adverse change in the company, which could limit future capital access.
• The company has no obligation to sell any shares under the ATM Agreement, meaning capital raise is not guaranteed and depends on market conditions and company discretion.

Future Outlook

The company has the ability to offer and sell up to an additional $3,438,062 of common stock through its at-the-market program, providing a flexible mechanism for future capital raising as needed.

Management Comments

• No specific management comments or quotes were provided in this filing beyond the signature of the Chairman and CEO, Quang X. Pham, on the report.

Industry Context

At-the-market offerings are a common financing tool, particularly for biotechnology and pharmaceutical companies like Cadrenal Therapeutics, allowing them to raise capital incrementally to fund ongoing research, development, and operational expenses without the immediate price impact of a large, underwritten offering.

Stakeholder Impact

• Shareholders: Potential dilution from the issuance of new common stock, which could impact per-share value.
• Company (Management/Operations): Enhanced financial flexibility and access to capital to fund ongoing operations and strategic initiatives.
• Sales Agent (H.C. Wainwright & Co., LLC): Will earn 3.0% commission on gross sales, generating revenue for their services.

Next Steps

• The company may offer and sell shares of common stock from time to time under the ATM Agreement, subject to market conditions and company discretion.

Key Dates

Recommendation

The filing details a routine capital raising mechanism via an at-the-market offering. While it provides the company with financial flexibility, the potential for shareholder dilution suggests a neutral stance. The core investment thesis remains unchanged by this procedural update, warranting a 'hold' recommendation.

Keywords

Cadrenal Therapeutics, ATM Offering, Common Stock, Equity Offering, Capital Raise, SEC Filing, Form 8-K, CVKD